Anuh Pharma (ANUHPHR) Fundamentals 2026 — P/E 19.7x, Revenue Analysis | SniperIQ
Anuh Pharma (ANUHPHR) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹808 Crore, trading at ₹80.66 on the NSE. This SniperIQ fundamentals page covers Anuh Pharma's valuation (P/E 19.7x, P/B 2.3x), profitability (net margin 5.3%), revenue (₹772 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anuh Pharma's market cap?
Anuh Pharma (ANUHPHR) has a market capitalization of approximately ₹808 Crore, trading at ₹80.66 on the NSE. Market cap moves with the live share price.
What is Anuh Pharma's P/E ratio?
Anuh Pharma's trailing twelve-month P/E ratio is 19.7x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anuh Pharma?
Anuh Pharma runs a net profit margin of 5.3%, a gross margin of 19.8%, and an operating margin of 6.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anuh Pharma generate?
Anuh Pharma reported revenue of ₹772 Crore for fiscal year 2025, with net income of ₹41 Crore and earnings per share (EPS) of 4.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anuh Pharma pay a dividend?
Anuh Pharma offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Anuh Pharma financially healthy?
Anuh Pharma carries a debt-to-equity ratio of 0.00x and a current ratio of 2.22x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anuh Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anuh Pharma (ANUHPHR) the key facts are: market cap ₹808 Crore, P/E 19.7x, revenue ₹772 Crore, 52-week range 67-104.09. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anuh Pharma's full fundamentals live
Get Anuh Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.